Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Optibrium Ltd
Optibrium Ltd
Activities:
Research & Development
Digital
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Optibrium launches a metabolism prediction software platform tailored to DMPK scientists
Semeta can be used for the prediction of Phase I and II metabolic routes, sites, products and liabilities in early drug discovery
Finance
Optibrium acquires 3D drug design specialist BioPharmics
Following the acquisition, BioPharmics’ Drs Ajay Jain (CEO) and Ann Cleves (Director of Applied Science) join the Optibrium team as VP in the newly-created BioPharmics Division
Finance
Optibrium receives further investment from Kester Capital
Second round of funding from existing investors will further drive company expansion and commercial growth of its AI-enabled drug discovery technology
Finance
Optibrium appoints Prof Andy Black non-executive chair
Prior to his current roles, Black co-founded Kinapse, an international business providing expert advisory and implementation services to life science industries
Research & Development
Optibrium releases 3D design module for drug discovery software
This expansion is a result of a collaboration between BioPharmics and Optibrium
Finance
Optibrium and BioPharmics enter computational drug design collaboration
The Surflex eSim 3D module, planned for the 3rd quarter of 2021, will use BioPharmics’ 3D ligand-based design approaches
Drug Delivery
Optibrium launches AI software platform for drug discovery
It's the latest member of Optibrium's Augmented Chemistry platform of AI technologies
Subscribe now